In this study, we identify genes modified by the ZNF191 transcription factor with a combined strategy of transient overexpression and transient knockdown (KD) in a cellular model (HEK293), using oligonucleotide microarray technology. Several gene pathways were revealed by MAPPfinder to be involved in processes of the regulation of kinase activity, transcription, angiogenesis, brain development and response to DNA damage.
Pathway of regulation of kinase activity was significantly affected (Z-score 2.73). This pathway had a large number of expression changes, mostly due to the regulation of 12 genes (
GADD45B, SPRY4, DUSP6, RGS4, SPRED2, NRG1, EDN1, CCNA1, CDKN2B, CKS1B, SERTAD1 and
DUSP6), which were up-regulated in the
ZNF191-overexpressed cells and down-regulated in the
ZNF191 knockdown cells. In additional, 8 genes (
KITLG, PKIA, RB1, ZAK, PRKD3, C1QTNF6, C5 and
MAP4K5) were down-regulated in the
ZNF191-overexpressed cells and up-regulated in the
ZNF191 knockdown cells. A map of the genes involved in regulation of kinase activity was shown in Figure .
GADD45B, originally termed
MyD118, is first cloned as a myeloid differentiation primary response gene. It can be induced in the absence of protein synthesis following treatment of M1 myeloblastic leukemia cells with differentiation inducers[
34], suggesting that GADD45B play a role in hematopoiesis. KITLG is a pleiotropic factor that acts in utero in germ cell and neural cell development, and hematopoiesis[
35]. Accordingly,
ZNF191 has been isolated from bone marrow and promyelocytic leukemia cell lines [
26]. These data infer that ZNF191 may play a role in hematopoiesis.
Angiogenesis was another pathway markedly affected by ZNF191 (Z-score 2.31). As shown in Figure ,
CTGF, CYR61, EDN1, MYH9, NRP2, RUNX1, THBS1 were up-regulated in the
ZNF191-overexpressed cells, and down-regulated in the knockdown cells. In addition,
CEACAM1, PLXDC1, CXCL12, SEMA5A and
VEGF were down-regulated in the
ZNF191-overexpressed cells, and up-regulated in the knockdown cells. Angiogenesis, the growth of new blood vessels, is required for a variety of normal proliferative processes. Furthermore, angiogenesis is well established as also playing an important role in neoplastic growth and metastasis. VEGF is a potent stimulator of angiogenesis.
ZNF191 has been reported to be up-regulated in angiogenic tumor nodules where
VEGF expression is significantly decreased compared with preangiogenic nodules[
36]. In this study, our result in HEK293 cells is consistent with the findings that in human breast carcinoma cells overexpression of
ZNF191 results in a significant down-regulation of
VEGF, whereas silencing of
ZNF191 with small interfering RNA leads to increased
VEGF expression as well as the same inverse correlation between
ZNF191 and
VEGF observed in malignant tissues from human colon and breast biopsies [
36]. In addition, thrombospondin-1 (THBS1/TSP-1) has been shown to inhibit angiogenesis through direct effects on endothelial cell migration and survival, and through effects on vascular endothelial cell growth factor bioavailability. Aside from the inhibitory activity of angiogenesis, THBS1 also suppresses tumor growth by activating transforming growth factor beta and affects tumor cell function through interaction with cell surface receptors and regulation of extracellular proteases[
37]. The data in this study revealed that overexpression of
ZNF191 resulted in a significant up-regulation of
THBS1, whereas silencing of ZNF191 led to decreased
THBS1 expression in HEK293 cells. Taken together, these data suggest that ZNF191 may participate in negative regulation of angiogenesis. Furthermore, BMPR2 is overexpressed in the majority of human lung carcinomas independent of cell type[
38,
39]. PDGFR expression in colorectal cancer significantly correlates with lymphatic dissemination[
40]. MYO6 (myosin VI) is critical in maintaining the malignant properties of the majority of human prostate cancers diagnosed today[
41]. The finding that overexpression of
ZNF191 significantly down-regulated
BMPR2, PDGFR and
MYO6, whereas silencing of ZNF191 increased
BMPR2, PDGFR and
MYO6 expression suggests a tumor suppressor role for ZNF191 in human cancers.
The response to DNA damage node was significantly affected (Z-score 2.4), mostly due to the regulation of
BRCA1, BRCA2, ATM, BTG2 and
ATRX (Figure ). The most obvious explanation for this induction was that it was related to initiation of DNA replication. Indeed, DNA repair function is complementary to DNA replication, as the latter process is not error-free and produces mismatches that need to be repaired. However, we reported here that overexpression or elimination of
ZNF191 affected the upstream regulators of the DNA damage pathway, such as ATM, ATRX, BRCA2 and BTG2. These data suggest that ZNF191 may be involved in the control of DNA damage response in addition to the regulation of DNA replication and concurrent DNA repair. Microarray and real-time PCR showed that RB1, ATM, ATRX and BRCA1 genes were down-regulated in the
ZNF191-overexpressed cells (Figure ). Accordingly, RB1 knockdown by siRNA caused the down-regulation of ATM, ATRX and BRCA1[
42].
RB1 mRNA level was down-regulated in MCF-7 breast carcinoma cells by the overexpression of
ZNF191 (data not published).
Mice
Zfp191 transcript is detected early during embryogenesis in ectodermal, endodermal, mesodermal and extra-embryonic tissues. It is particularly observed in the developing central nervous system (CNS)[
43]. In rat,
ZNF191 mRNA is present at high levels in total embryonic head, and abundant in catecholaminergic tissues including substantia nigra, hypothalamus and olfactory bulb as well as peripheral catecholaminergic tissue adrenal medulla[
27]. In human,
ZNF191 transcript is also detected in brain[
27]. These studies demonstrate an important role of ZNF191 in brain development. Interestingly, in support with previous studies, our results showed a node affected by
ZNF191 was the brain development node (Z-score 2.27). 11 genes (
ATP7A, FOXP2, APAF1, ATM, CXCL12, SEPP1, SMARCA1, ATRX, NOTCH3, PRKG1, and
CEP290) down-regulated in the
ZNF191-overexpressed cells and up-regulated in the
ZNF191 knockdown cells (Figure ). The human copper-transporting ATP7A is essential for dietary copper uptake, normal development and function of the CNS, and regulation of copper homeostasis in the body[
44]. In addition, studies on Alzheimer's disease (AD) suggest an important role for copper in the brain, with some AD therapies focusing on mobilising copper in AD brains[
45]. The transport of copper into the brain is complex and involves numerous players, including amyloid precursor protein, A beta peptide and cholesterol[
45,
46]. Interestingly, in a yeast two-hybrid experiment using the SCAN domain of ZNF191 as bait, we identified that the zinc finger transcription factor ZNF191 can interact with NAE1(NEDD8 activating enzyme E1 subunit 1; amyloid beta precursor protein binding protein 1, 59 kDa) (unpublished data).
FOXP2 mutations in humans are associated with a disorder that affects both the comprehension of language and its production, speech[
47].
ZNF191 transcript was abundant in the mesencephalon, a structure that contains the major rat embryonic catecholaminergic tissues[
27]. Accordingly, ZNF191 can specifically interact with the widespread TCAT motif which constitutes the HUMTH01 microsatellite in the tyrosine hydroxylase (
TH) gene (encoding the rate-limiting enzyme in the synthesis of catecholamines)[
27]. Allelic variations of HUMTH01 are known to have a quantitative silencing effect on
TH gene expression and to correlate with quantitative and qualitative changes in the binding by ZNF191[
27]. In this study, overexpression of
ZNF191 resulted in a significant down-regulation of
TH, whereas knockdown of
ZNF191 resulted in a non-significant change of
TH level. The expression level of the TH gene is indistinguishable between the wild-type,
Zfp191+/-, and
Zfp191-/- mice[
32]. These data suggest that other genes may compensate at least in part for the loss of ZNF191 activity, ameliorating the effect of the
ZNF191 knockdown. Taken together, these data suggest that ZNF191 may be involved in the brain development and the neuropsychiatric diseases.
We have to point out that in the knockdown experiments we can only deduce the level of ZNF191 protein by the level of mRNA of ZNF191 because no antibody against the ZNF191 factor is commercially available and the turn-over of the protein is still unknown. So there is no mean to ascertain whether and when the ZNF191 protein is reduced significantly. In addition, in this study HEK293 cells were used as a cellular model to identify genes modified by the ZNF191 transcription factor. Some other cells could give at least partially over transcriptome modification. Furthermore, the transcriptional response found upon alteration of ZNF191 levels does not necessarily imply that this transcription factor regulates the differentially expressed genes. Many of the observed changes could be downstream and not direct effects of ZNF191 regulation. A proof of direct regulation would require a promoter analysis or some kind of DNA-protein binding experiment or in silico analysis.